Eli Lil­ly and Te­va pre­pare for court bat­tle over mi­graine med ri­val­ry

It looks like Eli Lil­ly and Te­va Phar­ma­ceu­ti­cals are go­ing to tri­al.

A fed­er­al ap­peals court on Mon­day re­fused to in­val­i­date three of Te­va’s patents for its mi­graine treat­ment Ajovy, while al­so de­clin­ing to is­sue a sum­ma­ry judg­ment in fa­vor of ei­ther com­pa­ny, which would ef­fec­tive­ly end the case with­out a full tri­al.

Te­va filed suit against Lil­ly back in 2018, al­leg­ing that the com­pa­ny in­fringed up­on nine patents with its ri­val mi­graine drug Em­gal­i­ty. The ri­val drugs were both ap­proved in Sep­tem­ber 2018 for the pre­ven­ta­tive treat­ment of mi­graine, and are de­signed to block cal­ci­tonin gene-re­lat­ed pep­tide (CGRP), a pro­tein as­so­ci­at­ed with the on­set of mi­graine pain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER